Eli Lilly shifts focus from obesity to tackling Alzheimer's, ALS, and chronic pain after success with GLP-1 drugs. With strong sales growth and stock price rise, the company plans to invest in high-impact research, including testing a new drug for Alzheimer's and advancing gene therapy.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay